Immunethep receives grant from Gates Foundation
Portuguese biotech company Immunethep has convinced the Bill & Melinda Gates Foundation to hand out a grant to test its antibody against the bacterial extracellular virulence factor GAPDH.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
EU researchers unveil how T cell dysfunction triggers MS
French and British scientists have revealed insight into how a critical immune regulatory pathway contributes to the development of multiple sclerosis (MS), potentially paving the way toward future immunotherapies for the debilitating condition.
Biofuels: study challenges EUs tank or table paradigm
A comprehensive sustainability assessment carried out by Cologne-based nova-Institute shows that first and second-generation bioethanol is feasible for the EUs climate strategy.
The study challenges the tank or table credo of many EU policymakers, which claims biofuels are unsustainable because they use arable land and thus compete with food production.
ADC Therapeutics raises US$200m in private financing
Swiss cancer antibody-drug conjugate (ADC) developer ADC Therapeutics Sarl (Epalinges) has raised US$200m million through an oversubscribed private placement. Investors include Auven Therapeutics, Redmile, the Wild Family Office and its development partner AstraZeneca.
Valuating biotechs benefits
European Biotech Week:?Highlighting the benefits biotechnology has brought to pharma development, agriculture and – last but not least – the bioeconomy, industry association EuropaBio celebrated the European Biotech Week with an exhibition, Discovering European Biotech Innovation, in the European Parliament in Brussels.
CureVac inks $1.7bn deal on mRNA cancer vaccines
mRNA cancer therapeutics specialist CureVac AG has baged US$50m upfront and is eglible to receive up to US$1.7bn in development milestones plus royalties for the development of five commercial cancer vaccines arising from a new R&D deal with Eli Lilly & Co. Lilly also made an equity investment of €45m.
Ablynx prices global offering
Belgian Nanobody® producer Ablynx NV said it aims to raise US$175m of its ordinary shares in a global offering, comprised of a public offering of American Depositary Shares ("ADS") in the US and Canada and an offer of ordinary shares in other countries through a private placement.
HPV vaccines: Cochrane Centres complaint vs safety review failed
A complaint against the EMAs handling of a referral procedure relating to potential side effects of Sanofi/MSDs HPV vaccine Gardasil and GSKs HPV jab Cervarix promoted by the Nordic Cochrane Centre and physicians has been rejected by the European Ombudsman.
CHMP upgrades Roches lung cancer drug Alecensa
The European Medicines Agency (EMA) has upgraded Roches Alecensa (Alectinib) from second-line to first-line treatment for patients with locally advanced of metastasing ALK-positive non-small cell lung cancer (NSCLC).
Exciting. Innovative. Berlin. A fast-growing ecosystem
Berlin is no longer well-known only for its amazing cultural landscape and clubbing locations. Today, the German capital is one of the top three European tech start-up cities. This is a major attraction for investors, big pharma companies, and high-class researchers from all over the world who come to settle in the HealthCapital region Berlin-Brandenburg. During BIO-Europe in November, it offers the opportunity to dive into a fast-growing life sciences ecosystem.